Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Discovery and Optimization of Novel Biphenyl Derivatives Bearing Cyclopropyl Linkage as Potent Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Inhibitors
Tongfei Jing, Zhijing Zhang, Zhenghui Kang, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 10, pp. 6811-6835
Closed Access | Times Cited: 13

Showing 13 citing articles:

Targeting PD-1/PD-L-1 immune checkpoint inhibition for cancer immunotherapy: success and challenges
Sadique A. Javed, Asim Najmi, Waquar Ahsan, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 18
Reducing PD-L1 Expression by Degraders and Downregulators as a Novel Strategy to Target the PD-1/PD-L1 Pathway
Zhijie Wang, L. Yuan, Xiaotong Liao, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 8, pp. 6027-6043
Closed Access | Times Cited: 5
Discovery of Novel d-(+)-Biotin-Conjugated Resorcinol Dibenzyl Ether-Based PD-L1 Inhibitors for Targeted Cancer Immunotherapy
Zongbao Ding, Shuanghu Wang, Yaru Shi, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 15, pp. 10364-10380
Closed Access | Times Cited: 10
Development of small molecule drugs targeting immune checkpoints
Luoyi Chen, Xinchen Zhao, Xiaowei Liu, et al.
Cancer Biology and Medicine (2024), pp. 1-18
Open Access | Times Cited: 3
Discovery of Novel Small-Molecule-Based Potential PD-L1/EGFR Dual Inhibitors with High Druggability for Glioblastoma Immunotherapy
Zichao Yang, Ziqing Liu, Shanhe Wan, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 10, pp. 7995-8019
Closed Access | Times Cited: 3
Discovery of Novel Non-Nucleoside Inhibitors Interacting with Dizinc Ions of CD73
Cunjian Shi, Longfeng Chang, Jie Wang, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 11, pp. 9686-9708
Closed Access | Times Cited: 2
Novel PD-L1/VISTA Dual Inhibitor as Potential Immunotherapy Agents
Chengliang Sun, Yao Cheng, Jingwen Dong, et al.
Journal of Medicinal Chemistry (2024)
Closed Access | Times Cited: 1
Establishment of Human PD-1/PD-L1 Blockade Assay Based on Surface Plasmon Resonance (SPR) Biosensor
Tess Puopolo, Huifang Li, Justin Gutkowski, et al.
BIO-PROTOCOL (2023) Vol. 13, Iss. 15
Open Access | Times Cited: 3
Synthesis and immunotherapy efficacy of a PD-L1 small-molecule inhibitor combined with its 131I-iodide labelled isostructural compound
Gao‐Chao Lv, Xin Hu, Nan Zhang, et al.
Bioorganic Chemistry (2024) Vol. 153, pp. 107810-107810
Closed Access
Sinulariapeptide F, a new peptide from culture broth of marine-derived fungus Simplicillium sp. SCSIO 41222
Yanchun He, Mengqin Wang, Qingqing Tie, et al.
The Journal of Antibiotics (2024) Vol. 78, Iss. 1, pp. 64-67
Closed Access
Beyond peptides: Unveiling the design strategies, structure activity correlations and protein-ligand interactions of small molecule inhibitors against pd-1/pd-l1
Pujan Sasmal, P. Prabitha, B. R. Prashantha Kumar, et al.
Bioorganic Chemistry (2024) Vol. 154, pp. 108036-108036
Closed Access
Virtual screening of drugs targeting PD-L1 protein
Kai-Dong Lin, Xiaoqian Lin, Xubo Lin
Acta Physica Sinica (2023) Vol. 72, Iss. 24, pp. 240501-240501
Open Access
Interaction of telmisartan and related sartans with the programmed cell death-ligand 1 (PD-L1) protein dimer: a molecular docking analysis
Gérard Vergoten, Christian Bailly
Future Journal of Pharmaceutical Sciences (2023) Vol. 9, Iss. 1
Open Access
Page 1

Scroll to top